Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
pCPA Revitalization
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Ibrance/fulvestrant (palbociclib/fulvestrant)
pCPA File Number:
21134
Negotiation Status:
Concluded with an LOI
Indication(s):
Advanced or Metastatic Breast Cancer
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
pCODR 10150
pCPA Engagement Letter Issued:
2019-08-14
Negotiation Process Concluded:
2020-04-08